PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: A comprehensive comparison

American Journal of Surgical Pathology

Volumn 35, Issue 12, 2011, Pages 1837-1847

  Ozcan, Ayhan ^a,b   Liles, Nathan ^a   Coffey, Donna ^a,c   Shen, Steven S ^a,c   Truong, Luan D ^a,b,c,d  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Department of Obstetrics Gynecology   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

endometrial and ovarian cancers; immunohistochemistry; metastasis; m llerian organs; PAX2 and PAX8 transcription factors

Indexed keywords

PAIRED BOX TRANSCRIPTION FACTOR; PAX2 PROTEIN, HUMAN; PAX8 PROTEIN, HUMAN; TRANSCRIPTION FACTOR PAX2; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIXED MULLERIAN TUMOR; NEOPLASM; PATHOLOGY; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIXED TUMOR, MULLERIAN; NEOPLASMS, GLANDULAR AND EPITHELIAL; PAIRED BOX TRANSCRIPTION FACTORS; PAX2 TRANSCRIPTION FACTOR; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 81355148626     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31822d787c     Document Type: Article

References (34)

1. Bouchard M. Transcriptional control of kidney development. Differentiation. 2004;72:295-306. (Pubitemid 41702122)
2. Bouchard M, Souabni A, Mandler M, et al. Nephric lineage specification by PAX-2 and PAX-8. Genes Dev. 2002;16:2958-2970. (Pubitemid 35334743)
3. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007;104:331-337. (Pubitemid 46135661)
4. Chivukula M, Dabbs DJ, O'Connor S, et al. PAX-2: a novel Mü llerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma. Int J Gynecol Pathol. 2009;28:570-578.
5. Cimino-Mathews A, Sharma R, Netto GJ. Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid. Am J Surg Pathol. 2011;35:757-761.
6. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31:1139-1148. (Pubitemid 47207115)
7. Dahl E, Koseki H, Balling R. PAX genes and organogenesis. Bioassays. 1997;9:755-765. (Pubitemid 27383751)
8. Grote D, Souabni A, Busslinger M, et al. PAX 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development. 2006;133:53-61. (Pubitemid 43169320)
9. Haynes CM, Sangoi AR, Pai RK. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens. Cancer Cytopathol. 2011;25:193-201.
10. Laury AR, Hornick JL, Perets R, et al. PAX-8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627-635.
11. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26:5284-5293.
12. Levanon K, Ng V, Piao HY, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. 2010;29:1103-1113.
13. Liu JF, Hirsch MS, Lee H, et al. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol. 2009;115:401-406.
14. Long KB, Srivastava A, Hirsch MS, et al. PAX8 Expression in welldifferentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol. 2010;34:723-729.
15. Mansouri A, Hallonet M, Gruss P. PAX genes and their roles in cell differentiation and development. Curr Opin Cell Biol. 1996;8:851-857. (Pubitemid 26399946)
16. Mansouri A, Chowdhury K, Gruss P. Follicular cells of the thyroid gland require PAX-8 gene function. Nat Genet. 1998;19:87-90. (Pubitemid 28242031)
17. Maulbecker CC, Gruss P. The oncogenic potential of Pax genes. EMBO J. 1993;12:2361-2367. (Pubitemid 23194186)
18. Mittag J, Winterhager E, Bauer K, et al. Congenital hypothyroid female PAX8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology. 2007;148:719-725. (Pubitemid 46143173)
19. Narlis M, Grote D, Gaitan Y, et al. PAX-2 and PAX-8 regulate branching morphogenesis and nephron differentiation in the developing kidney. J Am Soc Nephrol. 2007;18:1121-1129. (Pubitemid 46536898)
20. Nonaka D, Chiriboga L, Soslow RA. Expression of PAX8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566-1571.
21. Nonaka D, Tang Y, Chiriboga L, et al. Diagnostic utility of thyroid transcription factors PAX 8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2008;21:192-200. (Pubitemid 351172171)
22. Ozcan A, Ge Y, Rust M, et al. PAX-8 as a marker for renal, Mü llerian, and thyroid differentiation: a comprehensive study. Mod Pathol. 2010;23(Suppl 1):437A. (1946).
23. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in nonneoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. Advance online publication, February 11, 2011.
24. Plachov D, Chowdhury K, Walther C, et al. PAX-8, a murine paired box gene expressed in the developing excretory system and thyroid gland. Development. 1990;110:643-651. (Pubitemid 20330539)
25. Poleev A, Fickenscher H, Mundlos S, et al. PAX-8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. Development. 1992;116:611-223.
26. Rabban JT, McAlhany S, Lerwill MF, et al. PAX-2 distinguishes benign mesonephric and mü llerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol. 2010;34:137-146.
27. Sangoi AR, Karamchandani J, Kim J, et al. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10. Adv Anat Pathol. 2010;17:377-393.
28. Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX-2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Mü llerian system origin? Mod Pathol. 2007;20:856-863. (Pubitemid 47077268)
29. Tong GX, Weeden EM, Hamele-Bena D, et al. Expression of PAX 8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol. 2008;32:1380-1387.
30. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX 8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009;22:1218-1227.
31. Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005;29:1482-1489. (Pubitemid 41513298)
32. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135:92-109.
33. Tung CS, Mok SC, Tsang YT, et al. PAX-2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol. 2009;22:1243-1250.
34. Zhai QJ, Ozcan A, Hamilton C, et al. PAX-2 Expression in nonneoplastic, primary neoplastic, and metastatic neoplastic tissue: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2010;18:323-332.